Home » Topics » BioWorld Science

BioWorld Science
RSS

RubrYc Therapeutics closes series A financing

April 13, 2018

Phase I trial of TQB-2450 approved and initiated in China

April 13, 2018

ImmunoCellular Therapeutics achieves milestone in Stem-to-T-Cell program

April 13, 2018

CTA approval for ARGX-112 triggers milestone payment to Argenx

April 13, 2018

Mutation in FPN1 gene found to protect against malaria infection

April 12, 2018

Arbutus Biopharma and Roivant Sciences launch jointly owned Genevant Sciences

April 12, 2018

Pfizer initiates comparative phase III study of aztreonam/avibactam in Gram-negative infections

April 12, 2018

University of Oxford initiates phase I trial of MERS-CoV vaccine

April 12, 2018

Destiny's discussions with FDA clarify overall clinical trial plans for XF-73

April 12, 2018

Fujifilm Kyowa Kirin Biologics licenses rights to Mylan to commercialize adalimumab biosimilar

April 12, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...